Comment on CMS-2026-1256-0002

Summary: Omeros Corporation supports the proposed New Technology Add-on Payment (NTAP) for its biological therapeutic, YARTEMLEA, for the treatment of TA-TMA. The company requests that CMS finalize the NTAP status and set the maximum payment amount at $287,079 based on the clinical reality of using 12 full vials per inpatient stay.